Show simple item record

dc.contributor.advisorKassem, Iris Sen_US
dc.contributor.authorBogaard, Joseph Den_US
dc.date.accessioned2017-10-27T22:27:18Z
dc.date.available2017-10-27T22:27:18Z
dc.date.created2017-05en_US
dc.date.issued2017-04-06en_US
dc.date.submittedMay 2017en_US
dc.identifier.urihttp://hdl.handle.net/10027/21780
dc.description.abstractPurpose The purpose of this thesis work was to evaluate therapeutic interventions for the treatment of various eye disorders using preclinical and clinical studies. The prevention and treatment of postoperative inflammation and fibrosis after pediatric cataract surgery was investigated using a rabbit animal model. The timing of amblyopia therapy following pediatric ocular trauma was examined to determine if a delay in treatment had an effect on visual outcomes. Finally, lead optimization and efficacy studies were performed for a new therapeutic agent for retinal degenerations such as retinitis pigmentosa based on identification of sulfaphenazole from a cellular high throughput screen. Methods Biochemical, cellular, animal, and retrospective human studies were performed to evaluate the effectiveness of different drugs and treatment strategies. Rabbits were used as a model for clear cornea lensectomy procedures to evaluate enoxaparin, triamcinolone, and tissue plasminogen activator. A retrospective examination of all the pediatric cases of ocular trauma that were seen in UIC’s EEI for over 13 years were used to evaluate if the timing of amblyopia therapy affects visual outcomes. Biochemical studies of CYP inhibition, cell death studies with 661W and a mouse model of retinal degeneration were used to evaluate a candidate therapy and its analogs. Results Rabbit studies demonstrated a significant treatment benefit to both enoxaparin, a low molecular weight heparin, for the prevention fibrosis. The effect was augmented by enoxaparin in combination with a low dose intraocular steroid, preservative-free triamcinolone, with a reduction of multiple measures of inflammation and fibrosis. Tissue plasminogen activator was found to be an effective treatment to solubilize fibrin formed in the anterior chamber after lensectomy. In children under the age of 8 with a history of ocular trauma, visual acuity outcomes were improved if amblyopia therapy was initiated within the first three months after the initial injury. Despite promising results in the cell-based studies, our top sulfaphenazole analog, KB-2-001, showed no protection in animal studies. Conclusions There are several promising therapeutic strategies that may have clinical applicability in humans. In particular, preventing and treating children with a history of cataract in need of surgery or a history of ocular trauma demonstrated a significant efficacy that warrants further investigation with the potential to move forward to clinical trials. The prevention and treatment for inherited retinal diseases investigated of inherited retinal degenerations needs further studies before determining its potential therapeutic value.en_US
dc.format.mimetypeapplication/pdfen_US
dc.subjectNeuroscience, Ophthalmologyen_US
dc.titleEvaluation of Therapeutic Interventions for the Treatment of Eye Disordersen_US
dc.typeThesisen_US
thesis.degree.departmentNeuroscienceen_US
thesis.degree.grantorUniversity of Illinois at Chicagoen_US
thesis.degree.levelDoctoralen_US
thesis.degree.namePhD, Doctor of Philosophyen_US
dc.contributor.committeeMemberFreitag, Nancyen_US
dc.contributor.committeeMemberRosenblatt, Mark Ien_US
dc.contributor.committeeMemberPepperberg, Daviden_US
dc.type.materialtexten_US
dc.contributor.chairLarson, Johnen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record